Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL)

被引：1
|
作者：
Carlo-Stella, C.
Guidetti, A.
Viviani, S.
Bonfante, V.
Marchiano, A.
Gatti, B.
D'Urzo, C.
Di Nicola, M. A.
Corradini, P.
Gianni, A. M.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Italfarmaco SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3068
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
    Sanchez-Gonzalez, Blanca
    Yang, Hui
    Bueso-Ramos, Carlos
    Hoshino, Koyu
    Quintas-Cardama, Alfonso
    Richon, Victoria M.
    Garcia-Manero, Guillermo
    BLOOD, 2006, 108 (04) : 1174 - 1182
  • [22] Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Raje, Noopur
    Jagannath, Sundar
    Richardson, Paul
    Hari, Parameswaran
    Orlowski, Robert
    Supko, Jeffrey G.
    Tamang, David
    Yang, Min
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3307 - 3315
  • [23] Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
    O A O'Connor
    British Journal of Cancer, 2006, 95 : S7 - S12
  • [24] Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
    O'Connor, O. A.
    BRITISH JOURNAL OF CANCER, 2006, 95 (Suppl 1) : S7 - S12
  • [25] Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
    Redic, Kimberly A.
    Hough, Shannon M.
    Price, Erika M.
    ONCOTARGETS AND THERAPY, 2016, 9 : 2783 - 2793
  • [26] Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma
    Fedorova, L.
    Lepik, K.
    Mikhailova, N.
    Kondakova, E.
    Kotselyabina, P.
    Shmidt, D. I.
    Kozlov, A.
    Zalyalov, Y.
    Borzenkova, E.
    Baykov, V.
    Moiseev, I.
    Kulagin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S655 - S655
  • [27] Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
    Fedele, Roberta
    Martino, Massimo
    Recchia, Anna Grazia
    Irrera, Giuseppe
    Gentile, Massimo
    Morabito, Fortunato
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [28] The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
    Locatelli, Silvia L.
    Guidetti, Anna
    Cleris, Loredana
    Tartari, Silvia
    Gianni, Alessandro M.
    Anichini, Andrea
    Carlo-Stella, Carmelo
    BLOOD, 2012, 120 (21)
  • [29] PCI-24781, a novel histone deacetylase inhibitor (HDACI), induces caspase-dependent apoptosis in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) cell lines and is synergistic in combination with bortezomib
    Bhalla, S.
    David, K.
    Balasubramanian, S.
    Prachand, S.
    Mauro, L.
    Sirisawad, M.
    Buggy, J.
    Miller, R. A.
    Gordon, L. I.
    Evens, A. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [30] INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Walewski, J.
    Paszkiewicz-Kozik, E.
    Borsaru, G.
    Moicean, A.
    Warszewska, A.
    Strobel, K.
    Biggi, A.
    Hauns, B.
    Mais, A.
    Henning, S.
    Hentsch, B.
    HAEMATOLOGICA, 2010, 95 : S27 - S27
12345